Leading with innovation and expertise

Dr. Parva has 26 years of experience in pharmaceutical product development, from ANDA/505(b)(2) to drug discovery, with a doctorate in Drug Designing from Veer Narmad University. He is specialized in polymorph screening, QSAR-based toxicity evaluation, and cost-effective API development strategies. His background includes leading ANDA, 505(b)(2) design, IP strategy, and FDA query responses at Zydus and Amneal.

Dr. Ganesh Sangle has an outstanding track record of 17+ years in leading discovery and early clinical development of NCEs and 505(b)2. Core competencies include broad scientific expertise in the areas of rare diseases, oncology, pain, and metabolic diseases. Dr. Sangle earned a Ph.D. degree in Physiology & Pathophysiology, with a focus in diabetes from the University of Manitoba and postdoctoral fellowship at the University of Toronto, Canada. Contributed to 3 INDs and was instrumental in approval of Lipaglyn (Saroglitazar), Viltab SR 50mg, and O Vildalog 100 SR. He has 16 publications, 9 patents and 29 scientific abstracts at various national and international symposiums (US, Canada, and India). He has previously worked with Zydus, Ranbaxy, Novartis, Lupin and Wockhardt.

With a Ph.D. in Medicinal Chemistry, Dr. Gupta has 26 years of experience in synthesis and design of NCEs. He holds 10 patents and has 25 publications in peer-reviewed journals, contributing to four successful INDs. Dr. Sunil led projects across therapeutic areas such as metabolic disorders, inflammation, antimicrobials, cardiovascular diseases, oncology, and CNS. His work has been instrumental in the development of drugs like Lipaglyn, Emrok, Zaynich, and Miqnaf. He has previously worked with Torrent, Zydus, and Wockhardt Research Centre.

With a PhD in Life Sciences (Biochemistry) and an M.Sc. in Biochemistry, Dr. Vishal brings over 16 years of experience in drug discovery biology. He oversees all preclinical activities in cross-functional projects, leveraging his expertise gained from leading research centers and CROs across India. His extensive background covers preclinical pharmacology, DMPK studies across species, and toxicology study design aligned with regulatory standards. Skilled in molecular biology and ADME studies, Dr. Vishal is a versatile scientist dedicated to advancing small-molecule drug discovery research. he has previously worked with Zydus, Advinus, Syngene and Piramal.